120181-35-3 Usage
General Description
(R)-(-)-Mosapramine is a chemical compound that belongs to the class of a dopamine receptor antagonist. It is commonly used as an antipsychotic medication to treat symptoms of schizophrenia and other psychotic disorders. The compound works by blocking dopamine receptors in the brain, which helps to reduce symptoms of psychosis such as hallucinations and delusions. (R)-(-)-Mosapramine is also known for its high selectivity and affinity for dopamine D2 receptors, making it an effective and specific treatment for psychotic symptoms. Additionally, it is being researched for its potential use in treating other neurological disorders such as Parkinson's disease and bipolar disorder. Overall, (R)-(-)-Mosapramine is a valuable therapeutic agent in the management of psychotic symptoms and shows promise in the treatment of other neurological conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 120181-35-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,0,1,8 and 1 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 120181-35:
(8*1)+(7*2)+(6*0)+(5*1)+(4*8)+(3*1)+(2*3)+(1*5)=73
73 % 10 = 3
So 120181-35-3 is a valid CAS Registry Number.
120181-35-3Relevant articles and documents
Syntheses and biological activities of optical isomers of 3-chloro-5-[3- (2-oxo-1,2,3,5,6,7,8,8a-octahydroimidazo[1,2-α]pyridine-3-spiro-4'- piperidino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine (Mosapramine) dihydrochloride
Lashiro,Seioguchi,Fukuda,Marubayashi
, p. 1074 - 1078 (2007/10/02)
Mosapramine (1) is a new neuroleptic drug with an asymmetric carbon atom (8a) in its imidazopyridine ring. The enantiomers of this agent were synthesized to compare their biological activities, such as antiapomorphine activity, affinity for dopamine D2 receptor and acute toxicity. The key intermediates, (R)-(-)- and (S)-(+)-2-oxo-1,2,3,5,6,7,8,8a- octahydroimidazo[1,2-α]pyridine-3-spiro-4'-piperidines, were prepared by optical resolution of the corresponding (±)-compound and were treated with 3-chloro-5-(3-methanesulfonyloxypropyl)-10,11-dihydro-5H-dibenz[b,f]azepine to afford (R)-(-)-1 and (S)-(+)-1, respectively. There were few differences in the examined biological activities of the two enantiomers as their dihydrochlorides.
